Innovative cellular test systems
The focus of preclinical drug development is on obtaining proof and in characterizing the function of the target cellular structures. The molecular cell biology section at the NMI has developed innovative cellular testing systems based on fundamental discoveries in cell and neurobiology.
These allow effective active-substance research. The NMI concentrates on tumourigenesis and metastases formation as well as on the treatment of diseases of the central nervous system, such as autism and schizophrenia.
Effective drug research
In order to illustrate relevant pathomechanisms in cellular test systems, we use reverse genetic methods such as RNA interference and gene-editing (Crispr/Cas9). This process is complemented by patient-derived stem cells. Thus complex diseases such as autism and schizophrenia can be illustrated.
For the screening of dynamic processes, novel biosensors (chromobodies) have been developed, which allow the imaging of the effects of substances in living cells (highcontent imaging). The data is then evaluated. These innovative techniques can be complemented with biochemical, molecular and cellular analysis (HCA, 3-D image analysis, calcium imaging).